实践意义：日本针对广泛期小细胞肺癌老年患者开展的卡铂和伊立替康II/III期试验 - Suppr

Suppr

超能文献

Implications for practice: phase II/III trial of carboplatin and irinotecan for elderly patients with extensive-stage small-cell lung cancer in Japan.

作者信息

Maheshwari Shipra, Gentzler Ryan D

机构信息

Division of Hematology, Department of Medicine, University of Virginia Cancer Center, Charlottesville, VA, USA.

出版信息

J Thorac Dis. 2024 Sep 30;16(9):6342-6346. doi: 10.21037/jtd-24-279. Epub 2024 Sep 23.

DOI:10.21037/jtd-24-279

PMID:39444913

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11494565/

Abstract

摘要

相似文献

Implications for practice: phase II/III trial of carboplatin and irinotecan for elderly patients with extensive-stage small-cell lung cancer in Japan.

J Thorac Dis. 2024 Sep 30;16(9):6342-6346. doi: 10.21037/jtd-24-279. Epub 2024 Sep 23.

Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial.

Lung Cancer. 2023 Jul;181:107195. doi: 10.1016/j.lungcan.2023.107195. Epub 2023 Apr 22.

A Phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small-cell lung cancer (JCOG1201).

Jpn J Clin Oncol. 2015 Jan;45(1):115-8. doi: 10.1093/jjco/hyu166. Epub 2014 Oct 20.

A combination chemotherapy of carboplatin and irinotecan with granulocyte colony-stimulating factor (G-CSF) support in elderly patients with small cell lung cancer.

Lung Cancer. 2006 Aug;53(2):197-203. doi: 10.1016/j.lungcan.2006.05.004. Epub 2006 Jun 15.

A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin treatment in patients with extended disease small-cell lung cancer.

Ann Oncol. 2006 Apr;17(4):663-7. doi: 10.1093/annonc/mdj137. Epub 2006 Jan 19.

Phase I/II study of induction chemotherapy using carboplatin plus irinotecan and sequential thoracic radiotherapy (TRT) for elderly patients with limited-disease small-cell lung cancer (LD-SCLC): TORG 0604.

BMC Cancer. 2017 May 26;17(1):377. doi: 10.1186/s12885-017-3353-y.

Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.

Thorac Cancer. 2023 Oct;14(28):2890-2894. doi: 10.1111/1759-7714.15097. Epub 2023 Sep 7.

A phase II study of carboplatin and etoposide plus durvalumab for previously untreated extensive-stage small-cell lung cancer (ES-SCLC) patients with a poor performance status (PS): NEJ045A study protocol.

BMC Cancer. 2022 Nov 4;22(1):1135. doi: 10.1186/s12885-022-10222-1.

Should irinotecan or etoposide be used in combination with carboplatin for small cell lung cancer?

Nat Clin Pract Oncol. 2009 Mar;6(3):134-5. doi: 10.1038/ncponc1324. Epub 2009 Jan 20.

A feasibility study of carboplatin plus irinotecan treatment for elderly patients with extensive disease small-cell lung cancer.

Jpn J Clin Oncol. 2014 Feb;44(2):116-21. doi: 10.1093/jjco/hyt195. Epub 2013 Dec 13.

本文引用的文献

Carboplatin and irinotecan (CI) vs. carboplatin and etoposide (CE) for the treatment of extended-stage small-cell lung cancer in an elderly population: A phase II/III randomized control trial.

Lung Cancer. 2023 Jul;181:107195. doi: 10.1016/j.lungcan.2023.107195. Epub 2023 Apr 22.

A Geriatric Assessment Intervention to Reduce Treatment Toxicity Among Older Adults With Advanced Lung Cancer: A Subgroup Analysis From a Cluster Randomized Controlled Trial.

Front Oncol. 2022 Mar 31;12:835582. doi: 10.3389/fonc.2022.835582. eCollection 2022.

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN.

ESMO Open. 2022 Apr;7(2):100408. doi: 10.1016/j.esmoop.2022.100408. Epub 2022 Mar 10.

Lung Cancer in Japan.

J Thorac Oncol. 2022 Mar;17(3):353-361. doi: 10.1016/j.jtho.2021.11.020.

Extensive-Stage Small-Cell Lung Cancer: First-Line and Second-Line Treatment Options.

J Clin Oncol. 2022 Feb 20;40(6):671-680. doi: 10.1200/JCO.21.01881. Epub 2022 Jan 5.

First-line treatment for lung cancer among Japanese older patients: A real-world analysis of hospital-based cancer registry data.

PLoS One. 2021 Sep 20;16(9):e0257489. doi: 10.1371/journal.pone.0257489. eCollection 2021.

Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities.

Cancer Cell. 2021 Mar 8;39(3):346-360.e7. doi: 10.1016/j.ccell.2020.12.014. Epub 2021 Jan 21.

Small-cell lung cancer.

Nat Rev Dis Primers. 2021 Jan 14;7(1):3. doi: 10.1038/s41572-020-00235-0.

Pembrolizumab or Placebo Plus Etoposide and Platinum as First-Line Therapy for Extensive-Stage Small-Cell Lung Cancer: Randomized, Double-Blind, Phase III KEYNOTE-604 Study.

J Clin Oncol. 2020 Jul 20;38(21):2369-2379. doi: 10.1200/JCO.20.00793. Epub 2020 May 29.

Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial.

Lancet. 2019 Nov 23;394(10212):1929-1939. doi: 10.1016/S0140-6736(19)32222-6. Epub 2019 Oct 4.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验